Is the Bayer DCA 2000 acceptable as a screening instrument for the early detection of renal disease?

Annals of Clinical Biochemistry

Volumn 36, Issue 3, 1999, Pages 393-394

  Shephard, Mark D S ^a   Barratt, L J ^a   Simpson Lyttle, W ^b  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b Umoona Tjutagku Health Service   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCREENING; TURBIDIMETRY; URINALYSIS;

EID: 0033054461     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456329903600315     Document Type: Article

References (6)

1. Poulsen PL, Mogensen C. Clinical evaluation of a test for immediate and quantitative determination of urinary albumin-to-creatinine ratio. Diabetes Care 1998; 21: 97-8
2. New Zealand Society for the Study of Diabetes. Consensus statement: New Zealand guidelines for the detection and management of nephropathy in diabetes. N Z Med J 1996; 109: 378-81
3. Poulsen PL. Microalbuminuria: techniques of measurement. In: Mogensen C-E, ed. Microalbuminuria. A marker for organ damage. London: Science Press, 1996: 15
4. Hoy W. Renal disease in Australian Aboriginals. Med J Aust 1996; 165: 126-7
5. Hoy W. Markers for cardiovascular and renal morbidity: expectations for an intervention program in an Australian Aboriginal community. Clin Exp Pharmacol Physiol 1996; 23: S33-7
6. Hiar C. Clinical Summary Report. Performance of the DCA 2000 Microalbumin/Creatinine System. Elkhart, Indiana, USA: Bayer Corporation, USA, 1997